Table 2 Characteristics of patients
‘Orléans’ cohort | ‘Cochin’ cohort | Total (%) | |
|---|---|---|---|
Patient characteristics | |||
n | 8 | 21 | 29 |
Age | 58 (42–78) | 62 (31–92) | 61 (31–92) |
Female | 6 | 8 | 14 (64) |
Male | 2 | 13 | 15 (52) |
Obesity | 3 | 2 | 5 (17) |
Diseases | |||
Rheumatoid arthritis | 5 | 2 | 7 (24) |
Kidney graft | 2 | 0 | 2 (7) |
Ayelodysplasia | 1 | 0 | 1 (3) |
ANCA-associtaed vasculitis | 0 | 17 | 17 (60) |
Polychondritis | 0 | 1 | 1 (3) |
Lupus | 0 | 1 | 1 (3) |
Medications | |||
Rituximab (anti-CD20) | 5 | 17 | 22 (76) |
Infliximab (anti-TNF) | 1 | 1 (3) | |
Prednisone | 4 | 10 | 14 (48) |
Mycofenolate mofetil | 2 | 1 | 3 (10) |
Methotrexate | 0 | 3 | 3 (10) |
5-azacytidine | 1 | 0 | 1 (3) |
Tacrolimus | 1 | 0 | 1 (3) |
Cyclosporin | 1 | 0 | 1 (3) |
Vaccines | |||
1st doses | |||
Pfizer | 8 | 20 | 28 (97) |
AstraZeneca | 0 | 1 | 1 (3) |
2nd doses | |||
Pfizer | 8 | 20 | 28 (97) |
AstraZeneca | 1 | 1 (3) | |
3rd doses | |||
Pfizer | 8 | 20 | 28 (97) |
Moderna | 1 | 1 (3) | |
4th doses | |||
Pfizer | 3 | 3 | 6 (21) |
Previous COVID-19 | 0 | 1 | 1 (3) |
PrEP | |||
Ronapreve | 3 | 15 | 18 (62) |
Evusheld | 8 | 21 | 29 (100) |
